Abivax

Company

Related News

Abivax Aligns with FDA on Obefazimod NDA for Ulcerative Colitis, Remains on Track for 2026 Filing

Jul 31, 2026

Abivax aligned with FDA on obefazimod NDA strategy for ulcerative colitis, targeting filing by end‑2026. Phase 3 ABTECT data at ECCO 2026 showed early symptom relief and positive DSMB safety review. Leadership appointments support potential commercialization.

Abivax Presents First Anti-Fibrotic Evidence for Obefazimod at ECCO 2026

Feb 21, 2026

Abivax announced novel preclinical and clinical data for obefazimod at ECCO 2026, highlighting anti-fibrotic potential in Crohn's disease, favorable safety profile, and rapid onset of symptomatic relief in inflammatory bowel disease patients.